Cytotherapy

Article	Citations
Editorial Board	126
ESTABLISHING A NATIONAL REGULATORY POLICY AND FRAMEWORK FOR THERAPEUTIC USE OF CELL AND TISSUE THERAPIES IN SULTANATE OF OMAN.	72
CLINICALLY COMPLIANT MATRIX FOR HUMAN ES AND IPSC CULTURE FOR PRECLINICAL AND CLINICAL THERAPY	70
OPTIMIZATION OF AUTOMATED SELECTION AND LENTIVIRAL VECTOR MEDIATED TRANSDUCTION OF MSC	60
MICROPOROUS PARTICLE SCAFFOLDS FOR MESENCHYMAL STROMAL CELL EXPANSION AND ENHANCED IMMUNOMODULATORY FUNCTION	51
CARTAR WEB TOOL: A CASE STUDY UNVEILING PROMISING TARGETS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES IN COLORECTAL ADENOCARCINOMA	49
Aims and Scope	46
SAMPLE TYPE, BUT NOT STORAGE DURATION, IMPACTS POST-THAW CD34 VIABILITY ON CORD BLOOD UNITS	46
INVESTIGATING THE INTERPLAY BETWEEN GUT MICROBIOME, MONOCYTES/MACROPHAGES, AND OSTEOARTHRITIS	45
EFFECTS OF STORAGE TEMPERATURE ON VITAL PARAMETERS OF CLINICAL GRADE CRYOPRESERVED MESENCHYMAL STEM CELL FINAL PRODUCT	44
COMPARATIVE PROFILING OF MESENCHYMAL STEM CELL EXTRACELLULAR VESICLES FOR APPLICATION IN REGENERATIVE DERMATOLOGY	43
ECTOPIC EXPRESSION OF CD39, A KEY REGULATOR OF THE PURINERGIC SIGNALING PATHWAY, INCREASED THE IMMUNOMODULATORY PROPERTIES OF MSC-DERIVED EXTRACELLULAR VESICLES	42
Distinct effects of intravenous bone marrow-derived mesenchymal stem cell therapy on ischemic and non-ischemic lungs after ischemia-reperfusion injury	40
Predicting chimeric antigen receptor apheresis process volume	37
“Combined synergistic effects of concentrated growth factors and adipose-derived mesenchymal stem cells on regeneration of induced mandibular defects in rabbits”	36
EFFICIENT COST-EFFECTIVE MANUFACTURE OF A NON-VIRAL TRANSPOSON BASED NOVEL BAFF-CART FOR TREATMENT OF B-CELL CANCERS	36
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy	34
Table of Contents	33
Editorial Board	33
Impact of Age and acute GVHD on Thymic Reconstitution Post-HCT: Insights from Multicenter Immune Monitoring of Pediatric and Young Adult Patients	33
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-ba	33
The Impact of Prior Immunotherapy on Composition of Apheresis Material for CAR T-cell Therapy in Patients with B-Cell Acute Lymphocytic Leukemia (B-ALL)	30
MOUSE MESENCHYMAL STROMAL CELL POTENCY ASSAY IN CONTEXT OF USE IN ACUTE LUNG INJURY	30
Enhancing Gene Transfer Efficiency in Viral and Non-Viral Vectors for Therapeutic Delivery	27
Scalable Production of Hematopoietic Stem Cells and Microglia from iPSCs Using Stirred Tank Bioreactors for Consistent Cell Therapy Manufacturing	27

An innovative iPSC Reprogramming mRNA-LNP Kit for PBMC	26
Classification of Foreign Materials Found in Mesenchymal Stem/Stromal Cell Product Manufacturing	26
Improving single cell multiomic analysis of T and B cells with innovations enhancing cost-effectiveness and data quality	26
A Narrative Review of Islamic Bioethics and Regenerative Medicine: The Case of Amniotic Fluid Mesenchymal Stem Cells	26
The hyper-inflammatory ARDS microenvironment enhances MSC reparative capacity in a pre-clinical model of acute lung inflammation	26
ACOUSTIC BEADS: A NOVEL METHOD FOR CELL SORTING USING ACOUSTOPHORESIS	26
Thymic Regulatory NK Cells: A Therapeutic Target for Restoring Immune Balance in Chronic Graft-Versus-Host Disease (cGVHD).	25
Evaluating CAR T cell therapy processing with the Sefia™ expansion system using commercially available cell culture media	25
CUTTING-EDGE LIPID-BASED MICROBUBBLE PLATFORM: ENHANCING CELL SORTING	25
Elevating MSC-EV Analysis: Development and Qualification of a CD73 Bioactivity Assay	24
HYDROGEL MICROPARTICLE-BASED ARTIFICIAL ANTIGEN-PRESENTING CELL FOR EFFICIENT EXPANSION AND REACTIVATION OF NK CELLS EX VIVO.	24
CONSTRUCTION OF DEAD-CAS9 MACHINERY FOR ACTIVATION OF ENDOGENOUS NEUROPROTECTIVE TRANSCRIPTION FACTOR MAX IN VITRO	24
Initial Experience Implementing a Structured Review Service for Non-GLP Study Data Intended to Support Regulatory Submissions at an Academic Institution	24
Process Development and Manufacturing: IMPROVED DOWNSTREAM VIRUS PURIFICATION YIELD USING EXCIPIENT-GRADE RECOMBINANT ALBUMIN, EXBUMIN	24
Streamlined Production of Tumor-Associated Antigen-Specific T Cells (TAAT) from Antigen-Naïve Donors in a GREX Device Using Autologous Monocyte-Derived Dendritic Cells (MoDC) Manufactured in the Same	24
A Simple Approach to Monitor the Cryostorage of Hematopoietic Stem Cells	23
GENERATION AND OPTIMIZATION OF ANTI-CD19 CAR-T CELL FOR LEUKEMIA IMMUNOTHERAPY	23
Process Development and Manufacturing: CAR-T CELLS MANUFACTURED VIA POSITIVE AND NEGATIVE IMMUNOMAGNETIC T CELL SELECTION SHOW DIFFERENT TUMOR KILLING RATES, CYTOKINE PROFILES, AND γδ T CELL OUTPUT	23
Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with “no-option” critical limb ischemia; observations on feasibility of the autologous approach from a clin	22
Exosomes/EVs: REAL-TIME BIOPROCESS MONITORING FOR LARGE-SCALE PRODUCTION OF MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES	22
Immunotherapy: MULTI-CENTER GAMMA-DELTA T CELL CLINICAL TRIAL PRODUCT IDENTIFICATION USING NEW PRODUCT ATTRIBUTE AND NEW CODES FOR ISBT 128 LABELING	22
Mesenchymal Stem/Stromal Cells: EVALUATION OF SCALABLE ATTACHMENT-DEPENDENT EXPANSION SYSTEM FOR MESENCHYMAL STEM CELLS IN XENO- AND SERUM-FREE MEDIA	22
THERAPEUTIC BENEFIT OF HUMAN WHARTON’S JELLY MESENCHYMAL STROMAL CELLS IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS	22
Mesenchymal Stem/Stromal Cells: DEVELOPMENT OF ICH Q2 (R1) COMPLIANT IMMUNOPOTENCY ASSAY MEASURING MESENCHYMAL STROMAL CELLS MEDIATED T-CELL INHIBITION	22
GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELL LINES DERIVED FROM TWO BRAZILIAN PATIENTS WITH HUTCHINSON-GILFORD PROGERIA SYNDROME CARRYING C.1824 C>T MUTATION	21
iPSC: ENGINEERING 3D MICRO-COMPARTMENTS FOR HIGHLY EFFICIENT AND SCALE-INDEPENDENT EXPANSION OF HUMAN PLURIPOTENT STEM CELLS IN BIOREACTORS	21
PREPARATION OF MUSCLE-DERIVED STEM CELLS SPHEROIDS IN A SCAFFOLD-FREE MICROMOLDED HYDROGEL MAINTAINING THEIR MYOGENIC POTENTIAL	21
THE EFFECT OF THE PRO-APOPTOTIC RHTRAIL PROTEIN IN THE PRESENCE OR ABSENCE OF THE COMBINATION WITH THE HSV-1 VIRUS IN HEAD AND NECK TUMOR LINES	21
Process Development and Manufacturing: A NEEDLE-BASED AUTOSAMPLER FOR BIOREACTOR CELL MEDIA COLLECTION	21
Aims and Scope	21
iPSC: IDENTIFICATION AND VALIDATION OF VENTRICULAR-SPECIFIC SURFACE MARKER FOR HUMAN PLURIPOTENT STEM CELLS-DERIVED CARDIOMYOCYTES	21
Mesenchymal Stem/Stromal Cells: MULTIPOTENT MESENCHYMAL STROMAL CELLS FROM PATIENTS WITH SYSTEMIC SCLEROSIS HAVE PRESERVED CLONOGENICITY, IMMUNOPOTENCY AND IN VITRO ANTIFIBROTIC EFFECTS	20
Immunotherapy: A 3D VASCULARIZED MICROFLUIDIC MODEL OF THE TUMOUR MICROENVIRONMENT FOR ASSAYING PSC DERIVED CAR-T CELL FUNCTION	20
Mesenchymal Stem/Stromal Cells: CAN PRIMING APPROACHES IMPROVE THE IMMUNOREGULATORY CAPABILITY OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS TO TREAT PANCREATIC CANCER?	20
Mesenchymal Stem/Stromal Cells: TRANSFECTION OPTIMIZATION FOR GENERATING CLINICAL GRADE IL-10 mRNA ENGINEERED MSCS	20
Process Development and Manufacturing: ONE YEAR FROM VECTOR TO BEDSIDE: RAMPING UP A SUCCESSFUL IN-HOUSE CAR T-CELL MANUFACTURING PROGRAM USING A NOVEL TRI-SPECIFIC CAR T-CELL THERAPY FOR LYMPHOID MAL	20
Process Development and Manufacturing: MINIMIZING PARTICULATE CONTAMINATION IN SINGLE-USE SYSTEMS FOR BIOPHARMACEUTICAL AND PHARMACEUTICAL INDUSTRIES	20
Embryonic, Organ and Other Tissue Specific Stem Cells: EXPLORING THE ANTI-TUMOR EFFECTS OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELL SECRETOME ON PANCREATIC DUCTAL ADENOCARCINOMA CELLS IN CO	20
Safety and Efficacy of High-Dose Memory CD45RO+ Donor Lymphocyte Infusion in Pediatric Recipients after Hematopoietic Stem Cell Transplantation	19
Mesenchymal Stem/Stromal Cells: CELL CULTURE MEDIA (CCM) AND/OR LICENSING SIGNIFICANTLY AFFECTS THE GENE EXPRESSION, SECRETOME AND IMMUNE CELL INTERACTION CAPACITY OF UMBILICAL CORD DERIVED MESENCHYMA	19
SAFETY AND EFFICACY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF OCU400 MODIFIER GENE THERAPY FOR TREATMENT OF RETINITIS PIGMENTOSA	19
Welcome to ISCT 2023	19
Editorial Board	19
Tissue Engineering: AUTOLOGOUS 3D NEURAL IMPLANTS FOR SPINAL CORD INJURY	19
An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells (MSC) Committee perspectives on International Standards Organization/Technical Committee 276 Biobanking Standards for bone	18
FAPα-TARGETED IMMUNOTHERAPY WITH SIBROTUZUMAB AND HIGH AFFINITY FC-RECEPTOR EXPRESSING NK92 CELLS: A PROMISING APPROACH TO REVERSE FIBROSIS	18
Mesenchymal Stem/Stromal Cells: CELLULAR AGING SECRETES: A COMPARISON OF BONE MARROW DERIVED AND INDUCED MESENCHYMAL STEM CELLS AND THEIR SECRETOME OVER LONG TERM CULTURE	18
Human cornea-derived mesenchymal stromal cells inhibit T cells through indoleamine 2,3 dioxygenase	18
Regulatory advancements in Japan's conditional and time-limited approval scheme for regenerative medical products: the first guidance on the approval scheme and the second review for full approval of	18
Chimeric synthetic T cell receptor and antigen receptor receptors enable high-sensitivity T cell receptor-negative CD8αβ-CD3-positive T-cell development from human-induced pluripotent stem cells	18

A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”	18
INTER-DONOR VARIABILITY AND CELLULAR PROLIFERATION: THEIR IMPACT ON THE IMMUNOMODULATORY STRENGTH OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN T CELL-MEDIATED HEPATITIS	17
Secretome of bone marrow mesenchymal stromal cells cultured in a dynamic system induces neuroprotection and modulates microglial responsiveness in an α-synuclein overexpression rat model	17
ANALYSIS OF COLD CHAIN PROCESSES FOR INVESTIGATIONAL CELL THERAPY PRODUCT SHIPMENTS AND TRANSPORT BASED ON REAL-WORLD TEMPERATURE DATA	17
Programmed spontaneously beating cardiomyocytes in regenerative cardiology	17
Proteomics profile of mesenchymal stromal cells and extracellular vesicles in normoxic and hypoxic conditions	17
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity	17
Development of an induced pluripotent stem cell–specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products	17
PHENOTYPIC CHANGES IN MESENCHYMAL STROMAL CELLS AND THEIR EXTRACELLULAR VESICLES DURING SERIAL PASSAGING	16
FIXING THE FOUNDATION: A PROPOSED MODEL FOR CGT DEVELOPMENT	16
A NOVEL WORKFLOW TO EVALUATE, COMPARE, AND STANDARDIZE CELL VIABILITY ANALYTICS	16
BRIDGING SCALE-UP TO TRANSPLANTATION: PLURIPOTENT STEM CELL-DERIVED PANCREATIC ISLET ENCAPSULATION IN EMULSION-GENERATED HIGH CONCENTRATION ALGINATE BEADS	16
MESENCHYMAL STROMAL CELLS INFLUENCE THE EPIGENETIC LANDSCAPE OF TRAINED MACROPHAGES IN A CLINICALLY RELEVANT MODEL OF ALLERGIC ASTHMA	16
CLOT FORMATION IN CELLULAR APHERESIS PRODUCTS: OCCURRENCE, RISK FACTORS AND MITIGATION	16
ON-DEMAND HYDROGEL MICROCARRIER PRODUCTION BY INK-JET BIOPRINTING FOR STEM CELL LARGE-SCALE CULTIVATION	16
DATA-DRIVEN APPROACH TO GROWING A CELL AND GENE THERAPY (CGT) LABORATORY: MEMORIAL SLOAN KETTERING CANCER CENTER (MSKCC) CELL THERAPY LABORATORY (CTL) EXPERIENCE.	15
ATMP PATH2PATIENT: BUILDNING A REGIONAL ECOSYSTEM FOR CELL AND GENE THERAPY TRANSITION	15
ASSESSMENT OF THE XIOGENIX ARES X20+ AS AN AUTOMATED FILL-FINISH SOLUTION FOR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MANUFACTURING	15
CLINICAL IMPROVEMENT OF BELL’S PALSY AFTER SEQUENTIAL SECRETOME AND MESENCHYMAL STEM CELL THERAPY: A CASE REPORT	15
PROBETILITY: A FIRST-IN-HUMAN PHASE I/IIA TRIAL OF REPEATED AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTE ADMINISTRATIONS IN METASTATIC COLORECTAL OR PROSTATE CANCER	15
MSC-EVS AS IMMUNOMODULATORS OF B CELL ACTIVATION	15
MSC-DERIVED ADIPOSE SPHEROIDS OFFER A SUPERIOR OPTION FOR POLARIZING MACROPHAGES TO AN ANTI-INFLAMMATORY PHENOTYPE	15
ROBUST AUTOMATED LEUKAPHERESIS CRYO-PROCESSING ENABLES HIGH-QUALITY STARTING MATERIAL FOR BOTH AUTOLOGOUS AND ALLOGENEIC CAR-T CELL THERAPY MANUFACTURING	15
OPTIMIZING IPSC AGGREGATE EXPANSION: NOVEL SOLUTIONS FOR MEDIA EXCHAGE IN PERFUSION BIOREACTOR CULTURE.	15
A NOVEL SEMI-DECENTRALIZED MANUFACTURING MODEL FOR SCALABLE, POTENT, OFF-THE-SHELF NK CELL THERAPY FOR CANCER AND AUTOIMMUNE DISEASES	14
A POPULATION HEALTH-BASED APPROACH TO INFORM THE PROVISIONING OF GENE THERAPIES FOR SEVERE SICKLE ANEMIA IN A LARGE, VERTICALLY INTEGRATED, VALUE-BASED HEALTH CARE SYSTEM	14
SHIP1 DELETION ENHANCES CAR-NK CELL THERAPUETIC POTENTIAL IN DIFFUSE LARGE B CELL LYMPHOMA	14
Role of mesenchymal stromal cells derivatives in diabetic foot ulcers: a controlled randomized phase 1/2 clinical trial	14
FROM IPSC TO IMSC: TRANSCRIPTOMIC INSIGHTS INTO DIFFERENTIATION IN HUMAN AND EQUINE SPECIES AND COMPARISON WITH PRIMARY MSC	14
A comprehensive review of quantum bioreactor cell manufacture: Research and clinical applications	13
Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments	13
Investigating MSC immune suppressive function with quantitative phase microscopy and single-cell spatial lipidomics	13
2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway	13
Clinical trial assessing the safety and efficacy of human bone marrow-derived allogeneic mesenchymal stem cell therapy for chronic active antibody-mediated rejection in kidney transplant recipients	13
Therapeutic Potential of First-Trimester Human Umbilical Cord Perivascular Cells in Mitigating Age-Related Muscle Dysfunction in a Natural Mouse Model of Aging	13
Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: results of a phase 1 clinical trial with 2-year follow-up	13
Advancing Wound Healing with Pre-Activated Umbilical Cord Mesenchymal Stem Cell Secretome	13
Detection of very small embryonic-like stem cells (VSELs) in the peripheral blood of rabbits subjected to induced retinal vein occlusion as a proposed early detection tool for the disease	12
Advancing CAR-NK Cell Engineering by Overcoming Transduction Challenges	12
LONG-TERM TOLERANCE TO LEYDIG CELL TRANSPLANTATION WITH LOCALIZED TREG IMMUNOMODULATION USING THE NANOLYMPH PLATFORM	12
AdoShell®, a non-fibrotic encapsulation system for cell delivery	12
ENEPC-CLI-01- A PHASE 2 DOUBLE BLIND PLACEBO CONTROLLED STUDY FOR AUTOLOGOUS BGC-101, ENRICHED ENDOTHELIAL PROGENITOR CELLS, FOR CRITICAL LIMB THREATENING ISCHEMIA	12
Key Strategies for Successful Equipment Qualification in Cell Therapy GMP	12
EXPLORING INNOVATIVE BIOREACTOR SYSTEM FOR END-TO-END T CELL MANUFACTURING	12
IMPROVED UNDERSTANDING OF CELL FATE USING A KIDNEY NORMOTHERMIC MACHINE PERFUSION MODEL	12
Accelerating sterility testing: Symcel calScreener+ achieves results in <3 days with direct inoculation in non-destructive and continuous monitoring system	12
Particulate Management in Bioprocessing: Challenges, Strategies, and Solutions	12
Results of the Phase I/IIb EXCELLENT trial evaluating the safety and efficacy of transendocardial injection of expanded autologous CD34+ cells in patients with recent myocardial infarction	12
BIOMATERIAL-ENABLED MACROPHAGE CELL THERAPY VIA DEXAMETHASONE-LOADED MICROPARTICLES FOR REGENERATIVE MEDICINE	11
AUTOANTIGEN-SPECIFIC REGULATORY T CELLS HALT THE PROGRESSION OF LUPUS NEPHRITIS	11
MANUFACTURE OF A BANK OF “OFF-THE-SHELF” CD30.CAR-EBVSTS FOR THE TREATMENT OF LYMPHOMA	11
CD73 activity of mesenchymal stromal cell-derived extracellular vesicle preparations is detergent-resistant and does not correlate with immunomodulatory capabilities	11
IMPLEMENTING CUSTOM PARTICLE SWARM-DIFFERENTIAL EVOLUTION OPTIMIZATION (PSODE) FOR GFP PLASMID DNA TRANSFECTION IN JURKAT AND PRIMARY T CELLS	11
ABSOLUTE QUANTIFICATION OF GENOMIC TARGETS FOR CELL COUNTING USING DROPLET DIGITAL PCR	11
NON-VIRAL GENOME EDITING IN HEMATOPOIETIC STEM CELLS (HSCS) FOR CELL-THERAPY APPLICATIONS - FROM DISCOVERY TO MANUFACTURING	11
Scientific venturing for early-stage professionals (ESPs), a key concept in the innovation ecosystem	11
BACK TO BASICS: A SCIENTIFIC AND ECONOMIC EVALUATION OF ADHERENT AND SUSPENSION PROCESSING FOR AAV AT SCALE	11
INSIGHTS INTO SPATIOTEMPORAL DYNAMICS OF ALLOREACTIVE T CELL RESPONSE WITH γMSCS ADMINISTRATION	11
THE MULTI POTENTIALS OF PLACENTA CHORIODECIDUAL MEMBRANES-DERIVED-MSCS (PCMSCS) FOR DECIDUALIZATION AND ANGIO-MYOGENESIS	11
Graft-versus-host disease is associated with skewed γδ T-cell clonality after umbilical cord blood transplantation in children with nonmalignant diseases	10
IMMUNOMODULATORY POTENTIAL OF EXTRACELLULAR VESICLES DERIVED FROM MESENCHYMAL STEM CELLS OBTAINED BY ULTRAFILTRATION AND ULTRACENTRIFUGATION	10
Mesenchymal Stem/Stromal Cells: HUMAN MESENCHYMAL STEM CELL THERAPY IN SEVERE COVID-19 PATIENTS: 2-YEAR FOLLOW-UP RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	10
Immunotherapy: ANTI-GD2 CAR T CELLS AGAINST SMALL CELL LUNG CANCER	10
Mesenchymal Stem/Stromal Cells: THE INTERFERON-GAMMA-INDOLEAMINE 2,3-DIOXYGENASE 1 (IFN-G-IDO1) AXIS IS NOT INVOLVED IN THE MSC-MEDIATED IMMUNOSUPPRESSION OF ACTIVATED T CELL PROLIFERATION	10
Mesenchymal Stem/Stromal Cells: UPFRONT USE OF ALLOGENEIC CYTO-MSC IMPROVES RESPONSE AND SURVIVAL RATES IN PATIENTS WITH ACUTE GVHD: AN INTERIM ANALYSIS OF ONGOING PHASE I/II MULTICENTER CLINICAL STUD	10
Mesenchymal Stem/Stromal Cells: PATIENT RESPONSES TO MESENCHYMAL STROMAL CELL (MSC) THERAPY IN OSTEOARTHRITIS ARE ASSOCIATED WITH DIFFERENTIAL CLINICAL PHENOTYPES, MOLECULAR ENDOTYPES, AND MSC CRITICA	10
MESENCHYMAL STROMAL CELLS EXPRESSING DEGRON-HPV16 E5 AS A NOVEL CERVICAL CANCER VACCINE	10
BIOPOTENCY AND SURROGATE ASSAYS TO VALIDATE IMMUNOMODULATORY POTENCY OF EXTRACELLULAR VESICLES DERIVED FROM MESENCHYMAL STEM/STROMAL CELLS	10
2023 Gene Therapy Mini-Series	10
Regulatory Affairs, Quality Systems, Policy, and Ethics: EVALUATION OF PERCENTAGE CHANGE IN PRE-DONATION AND POST-DONATION LABORATORY VALUES AFTER REPEATED (MNC), APHERESIS DONATIONS	10
Immunotherapy: PHASE I CLINICAL TRIAL OF ANTI-MINOR HISTOCOMPATIBILITY ANTIGEN EXPANDED T CELLS TO TARGET LEUKEMIA RELAPSING AFTER ALLOGENEIC HLA-MATCHED TRANSPLANTATION	10
Gene Editing/Gene Therapies: GDA-501 HER-2 CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS: DUAL CYTOTOXICITY IN SOLID TUMORS MEDIATED VIA HER2 AND TRAIL	10
MULTIOMIC PROFILING OF EX VIVO EXPANDED CD45 (+)CD34(BRIGHT) CD38(-) CD90(+) CD49F(+)CELLS REVEALS NOVEL PATHWAYS FOR THE LONG-TERM MAINTENANCE OF HEMATOPOIETIC STEM AND PROGENITOR CELLS	10
A NEW ERA OF BIOLOGICS: THE ROLE OF SOUTH KOREA's REGULATORY SCIENCE CENTER IN ENSURING LONG TERM SAFETY	10
Mesenchymal stromal cells regulate THP-1–differentiated macrophage cytokine production by activating Akt/mammalian target of rapamycin complex 1 pathway	10
Immunotherapy: CONVERTING IMMUNOLOGICALLY “COLD” MICROSATELLITE-STABLE COLORECTAL CANCER TO “HOT” BY DNA METHYLTRANSFERASE INHIBITOR AND RADIATION TO ENHANCE THERAPEUTIC EFFICACY	10
Subscription information	10
Process Development and Manufacturing: SUPERIOR EXPANSION OF γδ T-CELL SUBSETS FOR SOLID TUMOR T-CELL THERAPY USING A CHEMICALLY-DEFINED NON-ANIMAL ORIGIN SERUM-FREE CULTURE MEDIUM	10
Mesenchymal Stem/Stromal Cells: EVALUATION OF THE EFFECT OF MEDIUM COMPOSITION ON THE PHENOTYPIC AND FUNCTIONAL ATTRIBUTES OF MESENCHYMAL STROMAL CELLS	10
IMMUNOMODULATORY POTENTIAL OF ENHANCED MSC-DERIVED EXTRACELLULAR VESICLES	10

Mesenchymal Stem/Stromal Cells: EFFECTS OF COLD STORAGE ON MITOCHONDRIAL BIOENERGETICS AND PROTEIN IN HUMANMSCS	9
iPSC: THE IPS DERIVED MESENCHYMAL STEM CELLS AMELIORATED LIVER FIBROSIS AND LIVER FATTY DEPOSITION IN NAFLD/MAFLD-RELATED CIRRHOTIC MICE	9
Mesenchymal Stem/Stromal Cells: SINGLE-CELL TRANSCRIPTOMICS COMPARISON OF CELL THERAPEUTICS IN OSTEOARTHRITIS	9
The donor genetic determinant of human thymopoiesis rs2204985 is associated with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients	9
BIOMANUFACTURING ARCHITECTURE STABILIZES MSC OUTPUT AND PROGRAMS EXTRACELLULAR VESICLE POTENCY IN VIVO	9
INFUSION PRODUCT INFLAMMATORY SIGNATURES PREDICT ICANS BUT NOT EARLY RESPONSE AFTER CD19 CAR-T	9
Mesenchymal Stem/Stromal Cells: CELL CERAMTM ASSOCIATED WITH HUMAN LEVATOR VELI PALATINI MUSCLE STROMAL CELLS TO BONE RECONSTRUCTION IN CRANIOFACIAL SYNDROMES	9
Subscription information	9
Gene Editing/Gene Therapies: A NOVEL WEIGHT-BASED APPROACH TO DETERMINE CELL TYPE SPECIFICITY FROM SINGLE CELL DATASETS	9
Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia	9
IDENTIFICATION AND CHARACTERIZATION OF NOVEL VIRAL OPEN READING FRAMES	9
INTEGRATED TARGETED DELIVERY AND PLURIPOTENT STEM CELL–DERIVED THERAPIES FOR REGENERATIVE MEDICINE	9
IMPLEMENTING A STABILITY-BASED EXPIRY STRATEGY FOR CRYOPRESERVED HEMATOPOIETIC PROGENITOR CELLS: REAL-WORLD EXPERIENCE FROM AN INDIAN TRANSPLANT CENTER	9
Gene Editing/Gene Therapies: ENHANCING ANTI-OXIDATION OF MESENCHYMAL STROMAL/STEM CELLS USING CRISPR/CAS9 FOR INFLAMMATORY AND ISCHEMIC-REPERFUSION INJURY	9
The peril of the promise of speculative cell banking: Statement from the ISCT Committee on the Ethics of Cell and Gene Therapy	9
Immunotherapy: THE BTLA-HVEM AXIS IS A CRUCIAL IMMUNE CHECKPOINT OF T CELL IMMUNOTHERAPIES FOR CANCER	9
Tissue Engineering: DEVELOPMENT OF A TISSUE-ENGINEERED PRODUCT FOR GINGIVAL RECESSION	9
ADVANCING MRNA THERAPEUTICS: LIPID NANOPARTICLES ENABLE SAFE AND EFFICACIOUS RNA LNP DELIVERY FOR REPEATED MRNA ADMINISTRATIONS IN NORMAL AND TUMOR-BEARING MICE.	9
ENGINEERING HUMAN PLATELET LYSATE-DERIVED EXTRACELLULAR VESICLES WITH TUMOR TARGETING PEPTIDE P28 FOR ENHANCED BREAST CANCER CELL UPTAKE	9
Challenging immunophenotyping of patients with sickle cell disease adversely affects gene therapy product manufacturing – case reports.	9
ALLOGENEIC OSTEOBLAST THERAPY COMBINED WITH CORE DECOMPRESSION FOR OSTEONECROSIS OF THE FEMORAL HEAD	8
EXTRACELLULAR VESICLES DERIVED FROM CLONALLY-EXPANDED IMMORTALIZED MESENCHYMAL STROMAL CELLS REDUCE PERIPHERAL AND NEUROINFLAMMATION IN PRE-CLINICAL SEPSIS	8
Real World Experience of a Single-Center Tumor Infiltrating Lymphocyte (TIL) Melanoma Therapy Program: primary referral to TIL infusion (Brain to Vein)	8
Impact of mesenchymal stromal/stem cell infusions on circulating inflammatory biomarkers in COVID-19 patients: analysis of a phase I-IIa trial	8
5-DAY NON-VIRAL CAR-T MANUFACTURING VIA ELECTROPORATION: PRESERVING POTENCY WHILE COMPRESSING TIMELINES	8
VIVOCELL: AN ACCESSIBLE DELIVERY SYSTEM WITH PROVEN EFFICACY FOR IN VIVO ENGINEERING OF T CELLS	8
DEVELOPMENT OF A NOVEL MEDIUM THAT FACILITATE SCALABLE SUSPENSION CULTURE OF PLURIPOTENT STEM CELLS TOWARD CLINICAL USE	8
Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies	8
Advanced therapies require soft skills: insights from a National Academies Working Group	8
Impact of lower concentrations of dimethyl sulfoxide on cryopreservation of autologous hematopoietic stem cells: a systematic review and meta-analysis of controlled clinical studies	8
DNMT INHIBITOR-BASED EPIGENETIC MODULATION DURING MANUFACTURING ENHANCES CAR T-CELL FUNCTION AND PERSISTENCE IN PEDIATRIC BRAIN TUMORS	8
TARGETING MICROGLIAL P2X7R USING NON-VIRAL SIRNA DELIVERED VIA AN INJECTABLE HYDROGEL AS A TREATMENT FOR DRUG-REFRACTORY TEMPORAL LOBE EPILEPSY	8
COST-EFFECTIVE MESENCHYMAL CELL EXPANSION USING CORNING CELLCUBE SYSTEMS AS A PRECURSOR TO LARGE-SCALE PRODUCTION	8
GENE THERAPY FOR RECOMBINASE DEFICIENT-SCID	8
THE ASSESSMENT OF WOMEN'S EDUCATION IN MEXICO ON CORD BLOOD (CB) BANKING AND ETHICAL IMPLICATIONS	8
Filling the gap: the workforce of tomorrow for CGT manufacturing as the sector advances	8
HUMAN MARROW-ISOLATED ADULT MULTILINEAGE INDUCIBLE CELLS-DERIVED EXTRACELLULAR VESICLES (MIA-EVS) EXHIBIT A CONDITIONING-RESISTANT MIRNA REGULATORY BACKBONE AND ENHANCED REGENERATIVE AND IMMUNOMODULAT	8
DACS: A BUOYANCY-BASED PLATFORM FOR INTEGRATED T CELL SORTING AND ACTIVATION IN CELL THERAPY MANUFACTURING	8
AUTOMATED GMP MANUFACTURING OF CYTOKINE-ACTIVATED NATURAL KILLER CELLS PRODUCES A POTENT AND SAFE CELL THERAPY PRODUCT FOR AML AND NEUROBLASTOMA	8
Dual-CAR NK cells targeting PD-L1 and ErbB2/HER2 eliminate solid tumor cells and prevent immune escape due to antigen loss	7
Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee	7
Increasing access to transplantation through telemedicine and patient navigation	7
INVESTIGATING THE ADVANCEMENTS IN MESENCHYMAL STEM CELLS AND THEIR SECRETOME: UNVEILING THE POTENTIAL FOR FACIAL REJUVENATION	7
Mesenchymal Stem/Stromal Cells: THE IMPORTANCE OF CHEMICALLY-DEFINED MEDIA IN HAIR FOLLICLE CELL CULTURE FOR HAIR LOSS CELL THERAPY	7
Living medicines: Training before handling	7
Prognostic factors and outcomes of tisagenlecleucel in relapsed or refractory B-cell malignancies: a single-center real-world study	7
Integrating cell confinement in a perfusion bioreactor improves iMSC extracellular vesicle production and potency	7
The imperative to investigate epigenetic and transcriptional fidelity in long-term cryopreserved hematopoietic stem and progenitor cells	7
STERILITY SAMPLING OF CELL, GENE, AND TISSUE THERAPY PRODUCTS (ATMPs)	7
Outcomes following hematopoietic cell transplantation for children, adolescents and young adults with relapsed acute lymphoblastic leukemia	7
PRE-CLINICAL CHARACTERIZATION OF ALLOCETRATM; A NOVEL MACROPHAGE REPROGRAMMING CELL THERAPY, FOR INTRA-ARTICULAR TREATMENT IN OSTEOARTHRITIS	7
MULTIOMIC ANALYSIS OF γMSC-SUPPRESSED ALLOREACTIVE T CELLS	7
COMPARATIVE CHARACTERIZATION OF HUMAN DERMAL MESENCHYMAL STROMAL CELLS FROM DIFFERENT ANATOMICAL LOCATIONS AND ACROSS THE LIFESPAN	7
Mesenchymal Stem/Stromal Cells: CHEMICALLY DEFINED BIOMATRICES FOR MSC MANUFACTURING – FROM ISOLATION TO MICROCARRIER-BASED EXPANSION	7
Mesenchymal Stem/Stromal Cells: TRANSCRIPTOMIC ANALYSIS OF HUMAN MESENCHYMAL STEM CELLS FROM UMBILICAL CORD EXPANDED WITH INACTIVATED GMP-GRADE HUMAN PLATELET LYSATE	7
Immunotherapy: IMPROVING CAR T CELL EFFICACY IN A PRECLINICAL MODEL OF BREAST CANCER THROUGH MODIFIED MANUFACTURING METHODS AND ADJUVANT THERAPY	7
Time course and mechanistic analysis of human umbilical cord perivascular cell mitigation of lipopolysaccharide-induced systemic and neurological inflammation	7
Compliance and cost control for cryopreservation of cellular starting materials: An industry perspective	7
ACTIVATION, EXPANSION, AND CULTURE OF HUMAN T CELLS INCORPORATING IMMUNOCULTTM CGMP-COMPLIANT ANCILLARY REAGENTS	7
MICROFLUIDICS IMPROVES LENTIVIRUS TRANSDUCTION EFFICIENCY	7
PROCESS DEVELOPMENT FOR SCALABLE ALLOGENEIC CAR-T MANUFACTURING IN STIRRED-TANK BIOREACTORS: PERFUSION OPTIMISATION, MULTI-LITRE SCALE-UP AND AUTOMATED HARVESTING	7
The emerging promise of induced pluripotent stem cells in clinical studies: a systematic scoping review of the literature and registered clinical trials	7
Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort	7
A PLATFORM FOR THE ISOLATION AND CHARACTERIZATION OF EXTRACELLULAR VESICLES - EXPLORING A COMPREHENSIVE COLLECTION OF HUMAN EV	7
Mesenchymal Stem/Stromal Cells: COMPARISON ON THE CURATIVE EFFECTS OF MESENCHYMAL STEM CELL TRANSPLANTATION AND LOW-DOSE INTERLEUKIN-2 TREATMENT ON SYSTEMIC LUPUS ERYTHEMATOSUS	7
CHARACTERIZATION AND EVALUATION OF GENETIC STABILITY OF URINE-DERIVED STEM CELLS	7
Aims and Scope	7
"ONE POT’" PRODUCTION OF CHIMERIC ANTIGEN RECEPTOR T CELLS IN A NOVEL BIOREACTOR DESIGN	7
EFFECTS OF IGF-1-OVEREXPRESSING MESENCHYMAL STROMAL CELL TRANSPLANTATION IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS	7
A Multi-Donor Characterization of Degradable Microscaffolds for Therapeutic T Cell Manufacturing	7
Embryonic, Organ and Other Tissue Specific Stem Cells: INFLAMMATORY CYTOKINE EFFECTS ON HEPATIC METABOLISM IN PRIMARY HUMAN HEPATOCYTES: A REVISED EVALUATION OF DONOR CELL FATE AFTER TRANSPLANTATION	6
Regulatory Affairs, Quality Systems, Policy, and Ethics: VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ ALERT® 3D™ AND VIRTUO™ SYSTEMS FOR HAEMA	6
EVALUATION OF IN VIVO TOXICITY OF CLINICAL-GRADE EXTRACELLULAR VESICLES DERIVED FROM HUMAN MESENCHYMAL STROMAL CELLS	6
Gene Editing/Gene Therapies: MOVING THE NEEDLE FOR CELL THERAPIES: A NEXT-GENERATION EX VIVO PLATFORM USING NANONEEDLES FOR PRECISION CARGO DELIVERY	6
VIABILITY, DIFFERENTIATION PROFILE AND GENIC EXPRESSION OF UMBILICAL CORD BLOOD HEMATOPOIETIC PROGENITOR CELLS CULTURED ON PLA/COL/HA/MSC-WJ CONSTRUCTS AS AN EX VIVO EXPANSION STRATEGY	6
THE AMETHYST (ADVANCED MESENCHYMAL ENHANCED CELL THERAPY FOR SEPTIC) TRIAL: A FIRST-IN-HUMAN, DOSE-ESCALATION PHASE 1 SAFETY TRIAL OF GENETICALLY ENHANCED MSCS (GEM00220) APPEARED SAFE AND WELL TOLERA	6
Advancing the Development of Innovative Human Platelet-Derived Exosomes for Enhanced Therapeutic Applications	6
Immunotherapy: INHOUSE MANUFACTURING OF CAR-T CELLS: MAKING QUALITY CAR-T CELL THERAPY MORE ACCESSIBLE TO THE GENERAL PUBLIC	6
Immunotherapy: UTILIZATION OF BIDIRECTIONAL PROMOTERS IN SLEEPING BEAUTY-BASED DUAL CHIMERIC ANTIGEN RECEPTOR T CELL	6
Editorial Board	6
Mesenchymal Stem/Stromal Cells: CARTILAGE REPAIR BY HUMAN PLACENTA-DERIVED MESENCHYMAL STEM CELLS AND HYALURONIC ACID HYDROGEL IN A MINIPIG MODEL	6
Process Development and Manufacturing: C3P3-G3 ARTIFICIAL EXPRESSION SYSTEM FOR HIGH PERFORMANCE LENTIVIRUS PRODUCTION WITH IMPROVED PREDICTED BIOSAFETY	6
Quantitative Predictive Cellular Analytics Driving Improvements in Advanced Therapy Development and Manufacturing	6
Immunotherapy: NK CELL EXPANSION USING SCALE UP BIOREACTORS FOR CELL THERAPY	6
Mesenchymal Stem/Stromal Cells: LOCAL MANUFACTURING PROCESSES CONTRIBUTE TO VARIABILITY IN HUMAN MESENCHYMAL STROMAL CELL (MSC) EXPANSION WHILE GROWTH MEDIA SUPPLEMENTS CONTRIBUTE TO VARIABILITY IN GE	6
Process Development and Manufacturing: ESTABLISHING CELL VIABILITY MEASUREMENTS THAT PREDICT PROLIFERATIVE CAPACITY IN A MODEL SYSTEM	6
Exosomes/EVs: ADIPOSE-DERIVED STEM CELL SECRETOME TRIGGERS TGFβ-PSMAD SIGNALING IN CHONDROCYTES AND IS A PROMISING THERAPY FOR OSTEOARTHRITIS MODEL	6
Mesenchymal Stem/Stromal Cells: EXTRACTS FROM CHLORELLA VULGARIS PROTECT MESENCHYMAL STROMAL CELLS FROM OXIDATIVE STRESS INDUCED BY HYDROGEN PEROXIDE	6
Gene Editing/Gene Therapies: EFFICIENT AND GENTLE NON-VIRAL ENGINEERING OF CELLS IN VITRO AND EX VIVO BY PHOTOPORATION	6
Process Development and Manufacturing: CHALLENGES AND SOLUTION FOR PERFORMANCE VALIDATION OF EM AUTOMATION	6
CHARACTERIZATION OF CANINE UMBILICAL CORD MESENCHYMAL STEM CELLS	6
Process Development and Manufacturing: EFFECT OF DONOR AND METHOD VARIABILITY ON BIOMANUFACTURING PROCESS ESTABLISHMENT	6
Mesenchymal Stem/Stromal Cells: ROLE OF REACTIVE OXYGEN SPECIES IN SUPPRESSION OF ALLOREACTIVE T-CELLS BY INTERFERON-GAMMA PRIMED-MESENCHYMAL STROMAL CELLS	6
Exosomes/EVs: MESENCHYMAL STEM CELL DERIVED EXTRACELLULAR VESICLES: A NEW TREATMENT PARADIGM FOR SOLD ABDOMINAL ORGAN TRANSPLANT PATIENTS WTIH ALLOGRAFT FAILURE AND GRAFT VERSUS HOST DISEASE	6
Tissue Engineering: AUTOFLUORESCENCE IMAGING IDENTIFIES KEY SUBSTRATE PROPERTIES TO SUPPORT STEM CELL-DERIVED CARDIOMYOCYTE DIFFERENTIATION	6